Prof Gavin Joynt speaking on 'Personalised Antibiotic Prescription in the Critically Ill Patient' #VTA23#critcare#FOAMcc
Antibiotics are different from fluids in that, although they are crucial in reducing mortality, their effect is not immediately apparent. The consequences of underdosing or overdosing are quite real though. #VTA23
We often worry about overdosing, but underdosing puts not only the individual patient at risk, but also other patients in (or coming to the unit) who may be exposed to the eventual MDR organisms that arise. doi.org/10.1128/AAC.02… #VTA23
It is often assumed that with renal dysfunction, a lower dose is required. However, with the cytokines, organisms and drugs used during critical illness, the free fraction of the antibiotic may be higher, and renal clearance (or RRT clearance) may be higher! #VTA23
There are algorithms to try personalise dosing in critically ill patients on RRT, but they can be quite cumbersome. doi.org/10.1093/cid/ci… #VTA23
The future probably involves a degree of dose adjustment, but truly hinges on therapeutic drug monitoring. #VTA23
Why do we put tracheostomies in patients though?
The rationale for a trachy in ICU is that there are respiratory mechanical benefit (compare to a tracheal tube and a native airway). There are many patient care benefits - oral care, feeding, etc... #VTA23
There are problems, including the potential for real patient harm. Tracheostomy emergencies are a problem. Complications (Immediate, Early and Late) are encountered in 30% of patients. #VTA23
Next is Donna Hamel, speaking on 'PEEP Titration and Recruitment' #VTA23#critcare#FOAMcc
PEEP is important - it improves oxygenation, and is an essential component of lung protective strategies.
But PEEP also has some problems - it can cause hypotension and increased pulmonary vascular resistance.
So how does one get optimal PEEP? #VTA23
Optimal PEEP has no clear universal definition.
Maybe we should look for appropriate PEEP - a PEEP value that results in adequate oxygenation with the lowest risk of overdistension. #VTA23
Prof Anthony Holley is speaking next on 'Respiratory Support in the Trauma Patient' #VTA23#critcare#FOAMcc
The 'trauma' patient is not a single disease entity, but ultimately a mechanism that is characterised by a shared multitude of pathophysiological patterns (TBI, lung contusion, etc...) and interventions (surgery, transfusion) that lead to some common disease processes. #VTA23
These common disease processes include TRALI, ARDS, TIC and many more.
Of concern, ARDS is not uncommon in trauma patients. #VTA23
Next up are two of the Occupational Therapists from CHBAH - Marche van der Heyden and Tiffany Fairbairn - speaking on 'Sensory Stimulation in Critical Care'. #VTA23#critcare#FOAMcc
Sensory stimulation is emerging in critical care as a modality to re-establish normal functioning. Our senses are our connection to the world. There are 8 (not 5!) senses - auditory, olfactory, gustatory, visual, tactile/touch, vestibular, proprioception and interoception. #VTA23
The lesser known of these - vestibular, proprioception and interoception - all are key in self-soothing...
Interoception is the sense how different parts of our 'deep' body are feeling. There are a few activities that include all 8 senses - for example eating. #VTA23
Midmorning #VTA23 session starting - lots of short talks so expect quick changes in topic! #critcare#FOAMcc
Michael Gentile - Is PARDIE Changing Our View of Paediatric ARDS? #VTA23#FOAMcc#critcare
PARDIE stands for Pediatric ARDS Incidence and Epidemiology study. This study is one of the results of the PALISI Conference Group. doi.org/10.1016/S2213-… #VTA23
Last up for the morning session is John Davies, who is talking about 'Mechanical Ventilation during ECMO: all, some or none'. #VTA23#FOAMcc#critcare
Essential to remember the components of lung protective ventilation - tidal volume, plateau pressure, respiratory rate, PEEP, FiO2. #VTA23
Do the rules of LPV change when the patient is on ECMO.
There is little doubt that (in appropriately selected patients) ECMO has a mortality benefit. Have a look at the CESAR and EOLIA trials: doi.org/10.1016/S0140-… doi.org/10.1056/NEJMoa… #VTA23